|Videos|April 19, 2022
JAK Inhibitors: Impact on Symptoms, Quality of Life, and Patient Outcomes in MF
Author(s)Srdan Verstovsek, MD, PhD
Srdan Verstovsek, MD, PhD, reviews how treatment with JAK inhibitors improves symptoms, quality of life, and patient outcomes in primary MF.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA converted the accelerated approval of pembrolizumab in TMB-high solid tumors to traditional approval, redefining TMB-high as at least 13 mut/Mb.
Following an end-of-phase 2 meeting with the FDA, Rgenta plans to start a phase 3 trial of oral RGT-61159 in adenoid cystic carcinoma in the first quarter of 2027.
The FDA granted fast track designation to SBE303, Samsung Bioepis’ investigational Nectin-4–targeting ADC, for advanced urothelial cancer following enfortumab vedotin.
The antibody-drug conjugate sofetabart mipitecan showed efficacy and safety, leading to selection of a phase 3 dose for the FRAmework-01 trial.
FDA grants orphan drug designation to onvansertib for relapsed or refractory CMML, boosting development of the PLK1 inhibitor after early signals of activity.
Findings highlight the need for individualized monitoring after discharge, despite low rates of severe toxicities.
During a live event, Robert Orlowski, MD, PhD, and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple myeloma.
The guidelines incorporate cosibelimab for locally advanced cutaneous squamous cell carcinoma after favorable results in the CK-301-101 trial.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
3
Real-World Data for Darolutamide vs Abiraterone Triplet Therapy in mHSPC
4
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
5